How this works
The math
What the labels say
- Zepbound, Mounjaro single-dose (tirzepatide)
- US: 21 days in total, up to 30 °C. EU, Mounjaro: 21 days in total, below 30 °C.
- KwikPen, multi-dose vial (tirzepatide)
- US: The earliest of 30 days after first use, 30 total days at room temperature, or 4 weekly doses. EU, Mounjaro KwikPen: 30 days after first use; 4 labeled injections per pen.
- Wegovy single-dose (semaglutide)
- US and EU: 28 days, up to 30 °C.
- Wegovy FlexTouch, Ozempic pen (semaglutide)
- US: 56 days after first use. EU: Semaglutide pens: FlexTouch and 4-dose pens, 6 weeks after first use. 8-dose pens, 8 weeks.12
- Compounded vial
- Use the earlier of the printed beyond-use date and 28 days after first use. FDA recommends discarding by 28 days even if a compounder gives a later date.3
Where a label counts total time out of the fridge, include earlier days out. Pills have no countdown here; follow their own storage instructions.
What the label shows
US
The US label gives 28 days out of the fridge at 8 to 30 °C (46 to 86 °F), before the cap is removed. The printed expiry still comes first.4
The US label gives 28 days out of the fridge at 8 to 30 °C (46 to 86 °F), before the cap is removed. The printed expiry still comes first.4
Discard at the earliest of 56 days after first use, 56 days outside the refrigerator, after 4 labeled injections, or the printed expiry. After first use, store at 15 to 30 °C (59 to 86 °F) or refrigerated. Protect from light and heat.4
For the prescribed four-injection use, the matching pen delivers 4 labeled injections of 0.5 mg, 1 mg or 2 mg. The US label gives 56 days after first use at 15 to 30 °C (59 to 86 °F) or refrigerated. Novo Nordisk also requires use or disposal within 56 days of first exposure to non-refrigerated temperatures, even before first use. The earlier limit and printed expiry come first. Discard after the 4 labeled injections, even if medicine remains. Select the use already on your prescription; ask your pharmacist if the prescribed use is unclear.56
The labeled starter use of the 2 mg/3 mL pen provides 4 injections of 0.25 mg followed by 2 injections of 0.5 mg. The US label gives 56 days after first use at 15 to 30 °C (59 to 86 °F) or refrigerated. Novo Nordisk also requires use or disposal within 56 days of first exposure to non-refrigerated temperatures, even before first use. The earlier limit and printed expiry come first. Discard after these 6 labeled injections, even if medicine remains. Select the use already on your prescription; ask your pharmacist if the prescribed use is unclear.56
The US label gives 28 days out of the fridge at 8 to 30 °C (46 to 86 °F), in the original carton. The printed expiry still comes first.5
The US label gives 21 days in total out of the fridge, up to 30 °C (86 °F). Count earlier days out too. The printed expiry still comes first.7
The US label says to discard after 30 days in total at room temperature, 30 days after first use, or 4 weekly doses, whichever comes first. Keep at or below 30 °C (86 °F). The printed expiry still comes first.7
The US label gives 21 days in total out of the fridge, up to 30 °C (86 °F). Count earlier days out too. The printed expiry still comes first.8
The US label says to discard after 30 days in total at room temperature, 30 days after first use, or 4 weekly doses, whichever comes first. Keep at or below 30 °C (86 °F). The printed expiry still comes first.8
Follow the compounded vial’s beyond-use date. FDA says to discard a multiple-dose vial within 28 days after first use, even if its instructions say longer. The earlier date comes first. Ask your pharmacist about its temperature limit.3
EU
The EU label gives 28 days out of the fridge, at or below 30 °C. The printed expiry still comes first.1
The EU label gives 42 days after first use for the FlexTouch, below 30 °C or refrigerated. Discard after 4 labeled injections, even if medicine remains. The printed expiry still comes first. Before first use, keep refrigerated; ask your pharmacist about any earlier room-temperature exposure.1
The EU label gives 42 days after first use for four-dose pens, below 30 °C or refrigerated. Discard after 4 labeled injections, even if medicine remains. The printed expiry still comes first. Before first use, keep refrigerated; ask your pharmacist about any earlier room-temperature exposure.2
The EU label gives 56 days after first use for eight-dose pens (0.5 mg or 1 mg), below 30 °C or refrigerated. Discard after 8 labeled injections, even if medicine remains. The printed expiry still comes first. Before first use, keep refrigerated; ask your pharmacist about any earlier room-temperature exposure.2
The EU label gives 28 days out of the fridge, at or below 30 °C. The printed expiry still comes first.2
The EU label gives 28 days out of the fridge, at or below 30 °C. The printed expiry still comes first.1
The EU label gives 21 days in total out of the fridge, below 30 °C. Count earlier days out too. The printed expiry still comes first.9
The EU label gives 30 days after first use for the KwikPen, below 30 °C. Discard after 4 labeled injections, even if medicine remains. The printed expiry still comes first. Before first use, keep refrigerated; ask your pharmacist about any earlier room-temperature exposure.9
Before you act on this
If a medicine was frozen, looks cloudy or discolored, has particles, or arrived warm, don’t use it. Ask your pharmacist.
A date doesn’t make a damaged medicine safe. Heat above 30 °C (86 °F) and direct light count against it too.
Always follow your doctor’s or prescriber’s advice and guidance. Talk to your prescriber before changing your dose.
For information only, not medical advice. Verify results with your healthcare provider; Onederland accepts no liability for use of these tools.
- Runs on this device. Nothing you type is sent anywhere.
- Every figure names its source, below.
- Education, not medical advice. Your prescriber comes first.
Sources
Sources
- EU product information for semaglutide for weight management (tablets: summary of product characteristics, section 4.2), updated 21 September 2026. ema.europa.eu
- EU product information: injectable semaglutide for type 2 diabetes. ema.europa.eu
- FDA: concerns with unapproved GLP-1 medicines, October 1, 2026. fda.gov
- Wegovy (semaglutide) injection and tablets, US prescribing information, revised 06/2026. accessdata.fda.gov
- Ozempic (semaglutide) injection, US prescribing information, revised 05/2026. accessdata.fda.gov
- Novo Nordisk Medical: GLP-1 receptor agonist storage and stability. novonordiskmedical.com
- Zepbound (tirzepatide) injection, US prescribing information, revised 08/2026. accessdata.fda.gov
- Mounjaro (tirzepatide) injection, US prescribing information, revised 08/2026. accessdata.fda.gov
- EU product information: tirzepatide. ema.europa.eu
- Japanese prescribing information: tirzepatide for obesity, September 2026. pmda.go.jp
- Japanese prescribing information: injectable semaglutide for obesity, June 2026. pmda.go.jp
Label sources last checked on October 30, 2026. Onederland summarizes them; your prescriber and the full prescribing information come first.
